FDA's Fertility & Maternal Health Drugs Advisory Panel
On the first day of its April 27-28 meeting, the committee will discuss the NDA for the slow release, subcutaneous contraceptive capsule Norplant (levonorgestrel). The Population Council, New York City, is the sponsor of the application. The following day, the panel will review Syntex' NDA for nafarelin acetate for treatment of endometriosis. The meeting will be held in conference room G in FDA's Parklawn Building.
You may also be interested in...
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.
Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.
After a high-profile launch early this year, first-mover Perrigo has recalled its albuterol sulfate aerosol in the US following complaints of inhalers failing to dispense due to “clogging.” The firm has revealed the expected financial impact of the move as well as commenting on how long it expects the product to be off the market, during which albuterol rivals Cipla and Lupin could benefit.